The aforesaid is also true with regard to his carrying the pistol in these circumstances, when the defendant's control of the weapon is not optimal, as was clarified in the instructions given to the defendant when he received a license for a weapon but a short time earlier (P/75, P/121).
- As for the defendant's being under the influence of drugs, with the defendant's consent, a blood sample was taken from him for the purpose of discovering traces of the drug. In this context, documents were submitted by Dr. Yariv Kanfi, an expert in the Toxicology and Pharmacology Laboratory at Sheba Tel Hashomer Hospital (P/10 - P/13). In a letter dated May 16, 2023, entitled "Preliminary Response" (P/12), Dr. Kanfi noted that in the initial examination conducted to detect drugs, there was a suspicion that a dangerous drug/metabolic product of a dangerous cannabis-type drug was found in the sample that was tested. From the laboratory results report dated May 18, 2023 (Exhibit 13), it appears that the level of THC-oic acid (a metabolic product of the active ingredient in cannabis) found in the defendant's blood is 31.0 nanograms per ml. Level E THC (the active ingredient in cannabis) found in the defendant's blood is 5.7 nanograms per ml.
- In his testimony, Dr. Kanfi explained these results and clarified that since the sample taken from the defendant was taken two days after his arrest, he was apparently a chronic user of cannabis (use about four times a week on average). He also assessed, against this background, that in view of the high concentration found in the defendant during the examination two days after the incident, the concentration of theTHC The blood in his blood at the time of the incident was higher, but close to the concentration found in the test. The witness also stated that in the present case, it can be roughly assessed that the defendant consumed cannabis within a few days before the examination.
- Beyond the high concentration of drug residues found in the defendant's blood, Dr. Kanfi explained that the results indicate regular use of the drug, as opposed to occasional use. In this context, too, the defendant tried in his versions to reduce his use of the drug, claiming that he does not use cannabis, except for occasional use in social circumstances. Thus, for example, in his interrogation of May 6, 2023 (P/2), the defendant claimed that he had experienced smoking cannabis, but did not smoke (P/2B, p. 12, paras. 13-19):
"Researcher No. 1, Gil Alon: Do you use cannabis?